Search This Blog

Wednesday, September 21, 2022

Adamis Misses in Phase 2/3 Trial of Tempol in COVID-19 Positive High-Risk Subjects


  • Interim data from the Phase 2/3 clinical trial of Tempol did not demonstrate statistical significance of its primary endpoint of clinical resolution of COVID-19 symptoms at day 14 versus placebo

  • Independent Data Safety Monitoring Board recommends halting the trial

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.